Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA

The FDA has cleared Tango Therapeutics Inc's (NASDAQ:TNGX) Investigational New Drug (IND) application for its lead program, TNG908.

  • TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to kill cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion. 
  • MTAP deletions occur in 10% - 15% of all human cancers.
  • Tango expects to initiate a Phase 1/2 trial in 1H of 2022, with preliminary safety and efficacy data expected in 1H of 2023.
  • Enrollment will be limited to patients with confirmed MTAP-deleted tumors. 
  • Related: Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm.
  • The Company is also working on Target 3, an undisclosed synthetic lethal target.
  • In animal studies, Target 3 inhibition, combined with an anti-PD1 antibody, resulted in complete regressions and the induction of immune memory against re-implantation of tumors.
  • Tango expects to advance a development candidate in the first half of 2022 and file an IND in 2023.
  • The Company anticipates advancing a development candidate for their ubiquitin-specific protease 1 (USP1) program in 2H of 2022.
  • Price Action: TNGX shares are down 5.96% at $7.81 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.